Teoh JYC, Leung CH, Wang MH, et al. - In this study, the cost-effectiveness of the prostate health index (PHI) for prostate cancer detection in Chinese men was explored. A Markov model was developed for Chinese male patients aged 50–75 years old. For all patients, the prostate-specific antigen (PSA) strategy was to offer TRUS-PB with increased PSA of 4–10 ng/mL.  Researchers estimated the cost per quality-adjusted life-years gained for both strategies. They compared incremental cost-effectiveness ratios in relation to the willingness-to-pay (WTP) threshold. They further conducted a one-way sensitivity analysis and probabilistic sensitivity analysis. They also developed a cost-effectiveness acceptability curves. The evidence suggested that for prostate cancer detection, a PHI-based screening strategy may be more cost-effective than a PSA-based strategy in Chinese men. These outcomes support the consideration of a PHI-based technique for prostate cancer in Hong Kong.